Pfizer is currently running trials for an extended-release, once-a-day version of its $4 billion blockbuster Lyrica. So far, the big pharma has seen mixed results, exceeding in treating fibromyalgia but failing to reduce epileptic seizure frequency, as it attempts to expand the drug's competitiveness against not just current foes like once-daily Cymbalta, but also future cheaper generics.
See more in the following video.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Pfizer: Win Some, Lose Some originally appeared on Fool.com.
David Williamson owns shares of Pfizer. Max Macaluso and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.